Rik de Greef - Concepedia

Author

Rik de Greef

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Han Witjes, R de Greef, R. De Greef, R. de Greef, Rik De Greef, Rik de Greef

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)MSD (Netherlands)Pfizer (United States)Centre for Human Drug Research Janssen (Belgium)

About

Rik de Greef is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.3K
2	Social Sciences	7	7	223
3	Health Sciences	1	1	27
4	Public Health	1	1	61
5	Allergy	1	1	11

Rik de Greef

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers Fran ois Donat, J Duret, Alix Santoni, Clinical Pharmacokinetics Fondaparinux SodiumMedicineClinical PharmacologyPharmacotherapyPharmacology	2002	203
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors Malidi Ahamadi, Tomoko Freshwater, Marita Prohn, CPT Pharmacometrics & Systems Pharmacology Pembrolizumab ClearanceImmunologyMetronomic ChemotherapyImmunotherapyAdvanced Solid Tumors	2016	147
Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer Kathryn H. Brown, Craig Comisar, Han Witjes, British Journal of Clinical Pharmacology	2016	141
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response Hongshan Li, Jingyu Yu, Chao Liu, Journal of Pharmacokinetics and Pharmacodynamics MedicinePharmacologyTime Dependent PharmacokineticsBest Overall ResponseImmune Checkpoint Inhibitor	2017	135
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab Andreas Lindauer, CR Valiathan, Khamir Mehta, CPT Pharmacometrics & Systems Pharmacology ImmunologyPharmacotherapyImmunotherapyPhysiologically-based Pharmacokinetic ModelingHumanized Monoclonal Antibody	2016	117
Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial Jeroen Elassaiss‐Schaap, Stefaan Rossenu, Andreas Lindauer, CPT Pharmacometrics & Systems Pharmacology Keynote-001 TrialConfirm ”Pembrolizumab PksPharmacotherapySystem Pharmacology	2016	112
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma MS Chatterjee, Jeroen Elassaiss‐Schaap, Andreas Lindauer, CPT Pharmacometrics & Systems Pharmacology ImmunologyPathologyImmunotherapyPharmacodynamic ModelingPopulation Pharmacokinetic/pharmacodynamic Modeling	2016	79
Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation Sunny Chapel, Matt Hutmacher, George M. Haig, The Journal of Clinical Pharmacology NeuropsychologyPsychopharmacologyExposure‐response AnalysisPharmacotherapySocial Sciences	2009	62
Effect of a High-Fat Meal on the Pharmacokinetics of 300-Milligram Posaconazole in a Solid Oral Tablet Formulation Wendy M. Kersemaekers, Peter Dogterom, Jialin Xu, Antimicrobial Agents and Chemotherapy Nutrition300-Milligram PosaconazoleOral SuspensionPharmacotherapyPharmacodynamic Modeling	2015	61
Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia Lena E. Friberg, Rik de Greef, Thomas Kerbusch, Clinical Pharmacology & Therapeutics	2009	61

Page 1